2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.99 (Poster) Switching to Subcutaneous Atezolizumab After Intravenous Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

PP01.99 (Poster) Switching to Subcutaneous Atezolizumab After Intravenous Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling

Back to course

Pdf Summary

A study was conducted to assess the pharmacokinetics (PK) of atezolizumab, an intravenous (IV) form of a PD-L1 inhibitor, when switched to subcutaneous (SC) administration in patients with completely resected non-small-cell lung cancer (NSCLC) or locally advanced/metastatic triple-negative breast cancer (TNBC). The study found that switching from IV to SC dosing resulted in a minor change in atezolizumab drug exposures, with a slightly higher geometric mean (GM) trough concentration (Ctrough) and a slightly lower GM weekly area under the curve (AUC) following the switch. However, these differences were not clinically meaningful as atezolizumab has a flat exposure-response relationship.<br /><br />The study also compared the PK profiles of different dosing regimens. It found that a dosing switch from 1680 mg IV every 4 weeks (Q4W) to 1875 mg SC every 3 weeks (Q3W) resulted in a higher GM Ctrough and a slightly lower GM weekly AUC. Similarly, a switch from 840 mg IV every 2 weeks (Q2W) to 1875 mg SC Q3W led to a higher GM Ctrough and a slightly higher GM weekly AUC.<br /><br />Baseline characteristics of patients in the IMpower010 and IMpassion130 trials were also analyzed. Patients in the IMpower010 trial had a higher median body weight and fewer female patients compared to the IMpassion130 trial.<br /><br />Based on these findings, the study suggests that patients can switch from atezolizumab IV to SC administration at any treatment cycle without a clinically meaningful change in systemic drug exposure. The study used population PK modeling and simulations to assess the PK profiles of different dosing regimens.<br /><br />Overall, this study provides valuable insights into the PK of atezolizumab when switched from IV to SC administration and supports the use of SC dosing as an alternative to IV administration, offering potential time savings for patients and healthcare providers.

Asset Subtitle

Stephanie Liu

Keywords

pharmacokinetics

atezolizumab

intravenous

subcutaneous

PD-L1 inhibitor

non-small-cell lung cancer

triple-negative breast cancer

dosing regimens

systemic drug exposure

population PK modeling